Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05444556 · ClinicalTrials.gov registry record · Phase 1
A Study of Imlunestrant (LY3484356) in Female Healthy Participants
A Phase 1 study of Healthy, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 113
- Enrollment target
- 3
- Study locations
NCT05444556 is a Phase 1 study of Healthy that has completed, run by Eli Lilly and Company. The registered enrollment target is 113 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05444556, a Phase 1 study of Healthy, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 113 participants
- Enrollment target
- 3
- Study locations
Study Summary
The main purpose of this study is to evaluate the effect of imlunestrant on repaglinide, omeprazole and dextromethorphan, and rosuvastatin and digoxin. The study will also investigate the effect of quinidine on imlunestrant in female healthy participants of non-childbearing potential. The safety and tolerability of imlunestrant will be investigated in female healthy participants of non-childbearing potential. The study will last approximately up to 32 days for each participant excluding the screening period.
Conditions Studied
Interventions
- DRUG Omeprazole
- DRUG Dextromethorphan
- DRUG Imlunestrant
- DRUG Repaglinide
- DRUG Quinidine
Study Locations (3)
California
- Altasciences Clinical Los Angeles, Inc - Cypress
Florida
- Qps-Mra, Llc - South Miami
Texas
- ICON Early Phase Services - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2022-07-07 |
| Est. Completion | 2022-11-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05444556
The ClinicalTrials.gov registry entry for NCT05444556 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (83% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 5 interventions - of which Omeprazole is the first listed.
NCT05444556 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT05444556 about?
NCT05444556 is a clinical study titled "A Study of Imlunestrant (LY3484356) in Female Healthy Participants". The main purpose of this study is to evaluate the effect of imlunestrant on repaglinide, omeprazole and dextromethorphan, and rosuvastatin and digoxin. The study will also investigate the effect of quinidine on imlunestrant in female healthy participants of non-childbearing potential. The safety and...
What is the current status of trial NCT05444556?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 113 participants. The study started on 2022-07-07. Estimated completion is 2022-11-02.
What conditions does trial NCT05444556 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT05444556?
The interventions under investigation include: Omeprazole (DRUG), Dextromethorphan (DRUG), Imlunestrant (DRUG), Repaglinide (DRUG), Quinidine (DRUG).
Who is sponsoring clinical trial NCT05444556?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05444556 being conducted?
This trial has 3 study locations across California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.